Woodford, Malin put $50m into Kymab
This article was originally published in Scrip
Cambridge, UK-based Kymab has raised $50m to complete a total $90m series B financing round which will allow the firm to further its drug discovery platform, Kymouse. Kymab, founded in 2009, has now raised a total of $120m in equity financing. The $50m is being invested by Woodford Patient Capital Trust and Malin. It follows on from $40m invested by the Wellcome Trust and the Bill and Melinda Gates Foundation earlier in the series B round.